0001178913-22-001120.txt : 20220315
0001178913-22-001120.hdr.sgml : 20220315
20220315161010
ACCESSION NUMBER: 0001178913-22-001120
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220314
FILED AS OF DATE: 20220315
DATE AS OF CHANGE: 20220315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pfost Dale R
CENTRAL INDEX KEY: 0001394663
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38807
FILM NUMBER: 22741174
MAIL ADDRESS:
STREET 1: ACUITY PHARMACEUTICALS INC
STREET 2: 3701 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd.
CENTRAL INDEX KEY: 0001534248
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813676773
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
BUSINESS PHONE: 972-77-331-0156
MAIL ADDRESS:
STREET 1: KIRYAT ATIDIM, BUILDING 7
CITY: TEL AVIV
STATE: L3
ZIP: 6158002
FORMER COMPANY:
FORMER CONFORMED NAME: Anchiano Therapeutics Ltd.
DATE OF NAME CHANGE: 20180906
FORMER COMPANY:
FORMER CONFORMED NAME: BioCancell Ltd.
DATE OF NAME CHANGE: 20111104
4
1
zk2227489.xml
X0306
4
2022-03-14
0
0001534248
Chemomab Therapeutics Ltd.
CMMB
0001394663
Pfost Dale R
1316 JEFFERSON AVE
NEW ORLEANS
LA
70115
1
1
0
0
Chief Executive Officer
American Depositary Shares
2022-03-14
4
P
0
1800
3.98
A
1800
D
American Depositary Shares
2022-03-14
4
P
0
700
3.97
A
2500
D
Option to Purchase American Depositary Shares
10.05
2021-10-25
4
A
0
459353
0
A
2031-10-25
American Depositary Shares
459353
459353
D
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
The options vest and become exercisable over a period of four (4) years with one quarter (1/4) of the options vesting on October 25, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service.
/s/ Matthew Rudolph, Attorney-in-Fact for Dale R. Pfost
2022-03-15